<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000490.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <bqmodel:isDescribedBy rdf:resource="local:00002"/>
    <bqmodel:isDescribedBy rdf:resource="local:00003"/>
    <bqmodel:isDescribedBy rdf:resource="local:00004"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:description xmlns:ns2="http://purl.org/dc/elements/1.1/">&lt;body xmlns="http://www.w3.org/1999/xhtml"&gt;
  &lt;div class="dc:title"&gt;Demin2013 - PKPD behaviour - 5-Lipoxygenase
inhibitors&lt;/div&gt;
  &lt;div class="dc:bibliographicCitation"&gt;
    &lt;p&gt;This model is described in the article:&lt;/p&gt;
    &lt;div class="bibo:title"&gt;
      &lt;a href="http://identifiers.org/pubmed/24026253" title="Access to this publication"&gt;Systems pharmacology models
    can be used to understand complex
    pharmacokinetic-pharmacodynamic behavior: an example using
    5-lipoxygenase inhibitors.&lt;/a&gt;
    &lt;/div&gt;
    &lt;div class="bibo:authorList"&gt;Demin O, Karelina T, Svetlichniy D,
  Metelkin E, Speshilov G, Demin O Jr, Fairman D, van der Graaf PH,
  Agoram BM.&lt;/div&gt;
    &lt;div class="bibo:Journal"&gt;CPT Pharmacometrics Syst Pharmacol
  2013; 2: e74&lt;/div&gt;
    &lt;p&gt;Abstract:&lt;/p&gt;
    &lt;div class="bibo:abstract"&gt;
      &lt;p&gt;Zileuton, a 5-lipoxygenase (5LO) inhibitor, displays complex
    pharmaokinetic (PK)-pharmacodynamic (PD) behavior. Available
    clinical data indicate a lack of dose-bronchodilatory response
    during initial treatment, with a dose response developing after
    ~1-2 weeks. We developed a quantitative systems pharmacology
    (QSP) model to understand the mechanism behind this phenomenon.
    The model described the release, maturation, and trafficking of
    eosinophils into the airways, leukotriene synthesis by the 5LO
    enzyme, leukotriene signaling and bronchodilation, and the PK
    of zileuton. The model provided a plausible explanation for the
    two-phase bronchodilatory effect of zileuton-the short-term
    bronchodilation was due to leukotriene inhibition and the
    long-term bronchodilation was due to inflammatory cell
    infiltration blockade. The model also indicated that the
    theoretical maximum bronchodilation of both 5LO inhibition and
    leukotriene receptor blockade is likely similar. QSP modeling
    provided interesting insights into the effects of leukotriene
    modulation.CPT: Pharmacometrics &amp;amp; Systems Pharmacology
    (2013) 2, e74; doi:10.1038/psp.2013.49; advance online
    publication 11 September 2013.&lt;/p&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div class="dc:publisher"&gt;
    &lt;p&gt;This model is hosted on 
  &lt;a href="http://www.ebi.ac.uk/biomodels/"&gt;BioModels Database&lt;/a&gt;
  and identified by: 
  &lt;a href="http://identifiers.org/biomodels.db/BIOMD0000000490"&gt;BIOMD0000000490&lt;/a&gt;.&lt;/p&gt;
    &lt;p&gt;To cite BioModels Database, please use: 
  &lt;a href="http://identifiers.org/pubmed/20587024" title="Latest BioModels Database publication"&gt;BioModels Database:
  An enhanced, curated and annotated resource for published
  quantitative kinetic models&lt;/a&gt;.&lt;/p&gt;
  &lt;/div&gt;
  &lt;div class="dc:license"&gt;
    &lt;p&gt;To the extent possible under law, all copyright and related or
  neighbouring rights to this encoded model have been dedicated to
  the public domain worldwide. Please refer to 
  &lt;a href="http://creativecommons.org/publicdomain/zero/1.0/" title="Access to: CC0 1.0 Universal (CC0 1.0), Public Domain Dedication"&gt;CC0
  Public Domain Dedication&lt;/a&gt; for more information.&lt;/p&gt;
  &lt;/div&gt;
&lt;/body&gt;</ns2:description>
    <ns3:title xmlns:ns3="http://purl.org/dc/elements/1.1/">Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors</ns3:title>
    <ns4:thumbnail xmlns:ns4="http://www.collex.org/schema#"
       rdf:resource="http://omex-library.org/BIOMD0000000490.omex/BIOMD0000000490.png"/>
    <ns5:thumbnail xmlns:ns5="http://www.collex.org/schema#"
       rdf:resource="http://omex-library.org/BIOMD0000000490.omex/curation_image.png"/>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns6:identifier xmlns:ns6="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1016/j.drudis.2011.10.001"/>
    <ns7:label xmlns:ns7="http://www.w3.org/2000/01/rdf-schema#">Balaji M. Agoram &amp; Oleg Demin. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. Drug Discovery Today 16, 23-24 (2011).</ns7:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <ns8:identifier xmlns:ns8="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1038/psp.2013.49"/>
    <ns9:label xmlns:ns9="http://www.w3.org/2000/01/rdf-schema#">O Demin, T Karelina, D Svetlichniy, E Metelkin, G Speshilov, O Demin, D Fairman, PH van der Graaf &amp; BM Agoram. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT: Pharmacometrics &amp;amp; Systems Pharmacology 2, 9 (2013).</ns9:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <ns10:identifier xmlns:ns10="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1007/s11095-011-0467-9"/>
    <ns11:label xmlns:ns11="http://www.w3.org/2000/01/rdf-schema#">Piet H. van der Graaf &amp; Neil Benson. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharmaceutical Research 28, 7 (2011).</ns11:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <ns12:identifier xmlns:ns12="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1186/1752-0509-6-141"/>
    <ns13:label xmlns:ns13="http://www.w3.org/2000/01/rdf-schema#">Tatiana A Karelina, Kirill V Zhudenkov, Oleg O Demin, Dmitry V Svetlichny, Balaji Agoram, David Fairman &amp; Oleg V Demin. Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach. BMC Systems Biology 6 (2012).</ns13:label>
  </rdf:Description>
</rdf:RDF>

